非増殖糖尿病性網膜症の世界市場レポート 2025年

非増殖糖尿病性網膜症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.0％で38億7,000万米ドルに成長します。予測期間の成長は、遠隔医療の採用、新規治療薬の開発、人工知能の統合、研究開発投資の増加、ヘルスケアインフラの拡大などに起因すると考えられます。予測期間の主な動向には、スクリーニングと診断への人工知能の採用増加、遠隔医療と遠隔モニタリングソリューションの需要増加、糖尿病網膜症治療への個別化医療アプローチの出現、予防戦略と早期介入への注目の高まり、糖尿病網膜症の管理における患者中心のケアモデルの役割拡大などがあります。

糖尿病有病率の増加は、今後数年間における非増殖糖尿病性網膜症市場の拡大を促進すると予想されます。糖尿病は、膵臓によるインスリン分泌不足や体細胞のインスリン耐性化による血糖値上昇を特徴とする慢性代謝疾患です。この疾患は主に、座りがちなライフスタイル、食生活の乱れ、遺伝的素因などの要因によって引き起こされます。糖尿病は、主に高い血糖値に長時間さらされることで、網膜の血管を損傷し、視力が低下し、失明する可能性があります。例えば、2024年6月、英国の政府機関である国民保健サービス（NHS）は、2023年にイングランドで50万人以上（54万9,000人）が新たに2型糖尿病を発症するリスクがあることが判明したと報告しました。これにより、GPに登録された非糖尿病性高血糖、または糖尿病予備軍の総数は361万5,330人となり、2022年の306万5,825人から大幅に増加し、20％近く上昇したことになります。その結果、糖尿病罹患率の増加が非増殖糖尿病性網膜症市場の成長に拍車をかけています。

非増殖糖尿病性網膜症市場の新興国市場は、患者の予後を改善し、眼科イメージングに革命をもたらすAI対応カメラの開発に注力しています。人工知能アルゴリズムを搭載したこれらのカメラは、診断や治療を目的とした眼球画像の撮影、分析、解釈を支援します。例えば、フィンランドの医療技術企業であるオプトメッド社は、2024年5月、軽度段階を超えた糖尿病網膜症を即座に検出するように設計されたハンドヘルドAI眼底カメラ、オプトメッド・オーロラAEYEを発表しました。この革新的なデバイスは、携帯性と人工知能のパワーを組み合わせ、様々な眼疾患の早期発見とモニタリングのための高品質な網膜画像を提供します。オプトメッド・オーロラAEYEは、AIアルゴリズムを活用して医療従事者の網膜画像の解析を支援し、糖尿病網膜症、緑内障、加齢黄斑変性などの疾患の迅速かつ正確な診断を可能にします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界非増殖糖尿病性網膜症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の非増殖糖尿病性網膜症市場：成長率分析
• 世界の非増殖糖尿病性網膜症市場の実績：規模と成長, 2019-2024
• 世界の非増殖糖尿病性網膜症市場の予測：規模と成長, 2024-2029, 2034F
• 世界非増殖糖尿病性網膜症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の非増殖糖尿病性網膜症市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗血管内皮増殖因子（VEGF）療法
• 眼内ステロイド注射
• レーザー手術
• 硝子体切除術
• 世界の非増殖糖尿病性網膜症市場病気の重症度別、実績と予測, 2019-2024, 2024-2029F, 2034F
• マイルドな非増殖糖尿病性網膜症
• 中程度の非増殖糖尿病性網膜症
• 重度の非増殖糖尿病性網膜症
• 世界の非増殖糖尿病性網膜症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• その他のエンドユーザー
• 世界の非増殖糖尿病性網膜症市場抗血管内皮増殖因子（VEGF）療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベバシズマブ（アバスチン）
• ラニビズマブ（ルセンティス）
• アフリベルセプト（アイリーア）
• ペガプタニブ（マクゲン）
• 世界の非増殖糖尿病性網膜症市場眼内ステロイド注射の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリアムシノロンアセトニド
• デキサメタゾンインプラント（オズルデックス）
• フルオシノロンアセトニドインプラント（イルビエン）
• 世界の非増殖糖尿病性網膜症市場レーザー手術の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 焦点レーザー光凝固術
• 汎網膜光凝固術
• 世界の非増殖糖尿病性網膜症市場硝子体切除術の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 硝子体切除術（PPV）
• 膜剥離硝子体切除術
• 水晶体硝子体切除術（白内障と硝子体切除を組み合わせた手術）

第7章 地域別・国別分析

• 世界の非増殖糖尿病性網膜症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の非増殖糖尿病性網膜症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非増殖糖尿病性網膜症市場：競合情勢
• 非増殖糖尿病性網膜症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Novartis AG
• Eli Lilly and Company
• Novo Nordisk A/S
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• Genentech Inc.
• Carl Zeiss Meditec AG
• ZEISS Group
• Santen Pharmaceutical Co. Ltd.
• Santen Inc.
• Topcon Corporation
• Lumenis Ltd.
• Alimera Science

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非増殖糖尿病性網膜症市場2029：新たな機会を提供する国
• 非増殖糖尿病性網膜症市場2029：新たな機会を提供するセグメント
• 非増殖糖尿病性網膜症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-proliferative diabetic retinopathy (NPDR) stands as a prevalent complication of diabetes mellitus, impacting the retina-the light-sensitive tissue lining the rear of the eye. NPDR manifests through alterations in the retina's blood vessels due to prolonged exposure to elevated blood sugar levels (hyperglycemia) associated with diabetes. Its management involves a blend of medical interventions, lifestyle adjustments, and routine eye examinations aimed at halting disease progression and preserving vision.

The primary treatments for non-proliferative diabetic retinopathy encompass anti-vascular endothelial growth factor (VEGF) therapy, intraocular steroid injection, laser surgery, and vitrectomy. Anti-vascular endothelial growth factor (VEGF) therapy entails the administration of medications that impede vascular endothelial growth factor (VEGF) to deter abnormal blood vessel growth within the retina. This treatment is prescribed across varying severity levels, including mild, moderate, and severe non-proliferative diabetic retinopathy, and is typically administered in hospitals, specialized clinics, ambulatory surgical centers, and similar healthcare settings.

The non-proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides non-proliferative diabetic retinopathy market statistics, including non-proliferative diabetic retinopathy industry global market size, regional shares, competitors with a non-proliferative diabetic retinopathy market share, detailed non-proliferative diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the non-proliferative diabetic retinopathy industry. This non-proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes and improved diabetes management.

The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.87 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to adoption of telemedicine, development of novel therapeutics, integration of artificial intelligence, increasing investments in research and development, and expansion of healthcare infrastructure. Major trends in the forecast period include increasing adoption of artificial intelligence for screening and diagnosis, rising demand for telemedicine and remote monitoring solutions, emergence of, personalized medicine approaches for diabetic retinopathy treatment, growing focus on preventive strategies and early intervention, and expanding role of patient-centered care models in managing diabetic retinopathy.

The growing prevalence of diabetes is expected to drive the expansion of the non-proliferative diabetic retinopathy market in the coming years. Diabetes is a chronic metabolic condition characterized by elevated blood glucose levels due to insufficient insulin production by the pancreas or the body's cells becoming resistant to insulin. The condition is primarily caused by factors such as sedentary lifestyles, poor dietary habits, and genetic predispositions. Diabetes leads to non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, mainly from prolonged exposure to high blood glucose levels, which results in impaired vision and potentially blindness. For example, in June 2024, the National Health Service (NHS), a UK-based government agency, reported that in 2023, over half a million (549,000) additional individuals in England were found to be at risk of developing type 2 diabetes. This brought the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, a significant increase from 3,065,825 in 2022, representing nearly a 20% rise. Consequently, the increasing incidence of diabetes is fueling the growth of the non-proliferative diabetic retinopathy market.

Key players in the non-proliferative diabetic retinopathy market are focusing on developing AI-enabled cameras to enhance patient outcomes and revolutionize ophthalmic imaging. These cameras, equipped with artificial intelligence algorithms, aid in capturing, analyzing, and interpreting eye images for diagnostic and therapeutic purposes. For instance, in May 2024, Optomed, a Finland-based medical technology company, introduced Optomed Aurora AEYE, a handheld AI fundus camera designed to instantly detect diabetic retinopathy beyond mild stages. This innovative device combines portability with the power of artificial intelligence to deliver high-quality retinal images for early detection and monitoring of various eye conditions. The Optomed Aurora AEYE utilizes AI algorithms to assist healthcare professionals in analyzing retinal images, enabling swift and accurate diagnosis of conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

In January 2022, Meteda S.r.l., an Italy-based nutrition solutions company, acquired Retmarker SA to strengthen its position in providing innovative solutions for chronic diseases such as diabetes, particularly in diabetic retinopathy screening. This strategic move enhances Meteda's ability to address healthcare needs on a broader scale and prevent blindness among individuals with diabetes worldwide. Retmarker SA, a Portugal-based biotechnology company, specializes in developing medical devices serving as biomarkers for the progression of diabetic retinopathy.

Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.

North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-proliferative diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-proliferative diabetic retinopathy (NPDR) market consists of revenues earned by entities by providing services such as ophthalmological consultations, optometric services, contract research services, and counselling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-proliferative diabetic retinopathy (NPDR) market also includes sales of fundus cameras, optical coherence tomography (OCT) machines, laser photocoagulation equipment, and injections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Proliferative Diabetic Retinopathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-proliferative diabetic retinopathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-proliferative diabetic retinopathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-proliferative diabetic retinopathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Intraocular Steroid Injection; Laser Surgery; Vitrectomy
• 2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy; Moderate Non-Proliferative Diabetic Retinopathy; Severe Non-Proliferative Diabetic Retinopathy
• 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
• Subsegments:
• 1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin); Ranibizumab (Lucentis); Aflibercept (Eylea); Pegaptanib (Macugen)
• 2) By Intraocular Steroid Injection: Triamcinolone Acetonide; Dexamethasone Implant (Ozurdex); Fluocinolone Acetonide Implant (Iluvien)
• 3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Photocoagulation
• 4) By Vitrectomy: Pars Plana Vitrectomy (Ppv); Membrane Peeling Vitrectomy; Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Proliferative Diabetic Retinopathy Market Characteristics

3. Non-Proliferative Diabetic Retinopathy Market Trends And Strategies

4. Non-Proliferative Diabetic Retinopathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Non-Proliferative Diabetic Retinopathy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Proliferative Diabetic Retinopathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Proliferative Diabetic Retinopathy Market Growth Rate Analysis
• 5.4. Global Non-Proliferative Diabetic Retinopathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Proliferative Diabetic Retinopathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Proliferative Diabetic Retinopathy Total Addressable Market (TAM)

6. Non-Proliferative Diabetic Retinopathy Market Segmentation

• 6.1. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Vascular Endothelial Growth Factor (VEGF) Therapy
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy
• 6.2. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Non-Proliferative Diabetic Retinopathy
• Moderate Non-Proliferative Diabetic Retinopathy
• Severe Non-Proliferative Diabetic Retinopathy
• 6.3. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Other End-Users
• 6.4. Global Non-Proliferative Diabetic Retinopathy Market, Sub-Segmentation Of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bevacizumab (Avastin)
• Ranibizumab (Lucentis)
• Aflibercept (Eylea)
• Pegaptanib (Macugen)
• 6.5. Global Non-Proliferative Diabetic Retinopathy Market, Sub-Segmentation Of Intraocular Steroid Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triamcinolone Acetonide
• Dexamethasone Implant (Ozurdex)
• Fluocinolone Acetonide Implant (Iluvien)
• 6.6. Global Non-Proliferative Diabetic Retinopathy Market, Sub-Segmentation Of Laser Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Focal Laser Photocoagulation
• Panretinal Photocoagulation
• 6.7. Global Non-Proliferative Diabetic Retinopathy Market, Sub-Segmentation Of Vitrectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pars Plana Vitrectomy (PPV)
• Membrane Peeling Vitrectomy
• Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)

7. Non-Proliferative Diabetic Retinopathy Market Regional And Country Analysis

• 7.1. Global Non-Proliferative Diabetic Retinopathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Proliferative Diabetic Retinopathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market

• 8.1. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Proliferative Diabetic Retinopathy Market

• 9.1. China Non-Proliferative Diabetic Retinopathy Market Overview
• 9.2. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Proliferative Diabetic Retinopathy Market

• 10.1. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Proliferative Diabetic Retinopathy Market

• 11.1. Japan Non-Proliferative Diabetic Retinopathy Market Overview
• 11.2. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Proliferative Diabetic Retinopathy Market

• 12.1. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Proliferative Diabetic Retinopathy Market

• 13.1. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Proliferative Diabetic Retinopathy Market

• 14.1. South Korea Non-Proliferative Diabetic Retinopathy Market Overview
• 14.2. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Proliferative Diabetic Retinopathy Market

• 15.1. Western Europe Non-Proliferative Diabetic Retinopathy Market Overview
• 15.2. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Proliferative Diabetic Retinopathy Market

• 16.1. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Proliferative Diabetic Retinopathy Market

• 17.1. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Proliferative Diabetic Retinopathy Market

• 18.1. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Proliferative Diabetic Retinopathy Market

• 19.1. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Proliferative Diabetic Retinopathy Market

• 20.1. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Proliferative Diabetic Retinopathy Market

• 21.1. Eastern Europe Non-Proliferative Diabetic Retinopathy Market Overview
• 21.2. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Proliferative Diabetic Retinopathy Market

• 22.1. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Proliferative Diabetic Retinopathy Market

• 23.1. North America Non-Proliferative Diabetic Retinopathy Market Overview
• 23.2. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Proliferative Diabetic Retinopathy Market

• 24.1. USA Non-Proliferative Diabetic Retinopathy Market Overview
• 24.2. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Proliferative Diabetic Retinopathy Market

• 25.1. Canada Non-Proliferative Diabetic Retinopathy Market Overview
• 25.2. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Proliferative Diabetic Retinopathy Market

• 26.1. South America Non-Proliferative Diabetic Retinopathy Market Overview
• 26.2. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Proliferative Diabetic Retinopathy Market

• 27.1. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Proliferative Diabetic Retinopathy Market

• 28.1. Middle East Non-Proliferative Diabetic Retinopathy Market Overview
• 28.2. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Proliferative Diabetic Retinopathy Market

• 29.1. Africa Non-Proliferative Diabetic Retinopathy Market Overview
• 29.2. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Proliferative Diabetic Retinopathy Market Competitive Landscape And Company Profiles

• 30.1. Non-Proliferative Diabetic Retinopathy Market Competitive Landscape
• 30.2. Non-Proliferative Diabetic Retinopathy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Non-Proliferative Diabetic Retinopathy Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. Eli Lilly and Company
• 31.4. Novo Nordisk A/S
• 31.5. Regeneron Pharmaceuticals Inc.
• 31.6. Bausch Health Companies Inc.
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Genentech Inc.
• 31.9. Carl Zeiss Meditec AG
• 31.10. ZEISS Group
• 31.11. Santen Pharmaceutical Co. Ltd.
• 31.12. Santen Inc.
• 31.13. Topcon Corporation
• 31.14. Lumenis Ltd.
• 31.15. Alimera Science

32. Global Non-Proliferative Diabetic Retinopathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Proliferative Diabetic Retinopathy Market

34. Recent Developments In The Non-Proliferative Diabetic Retinopathy Market

35. Non-Proliferative Diabetic Retinopathy Market High Potential Countries, Segments and Strategies

• 35.1 Non-Proliferative Diabetic Retinopathy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Proliferative Diabetic Retinopathy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Proliferative Diabetic Retinopathy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer